Pricol Ltd (BOM:540293) Q4 2025 Earnings Call Highlights: Strategic Investments and Market ...
Release Date: May 16, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Pricol Ltd (BOM:540293) reported a consolidated revenue growth of 18.69% for FY25 compared to FY24.
The company achieved a return on capital employed of 22.86% in FY25, indicating efficient use of capital.
Pricol Ltd (BOM:540293) has made strategic investments in R&D to develop new products, which are expected to yield results in 8 to 12 quarters.
The acquisition of the plastics business from Syndrome A Components Limited is expected to enhance efficiency and increase margins.
The company is confident about a significant revival in the two-wheeler market due to regulatory changes, which should positively impact future revenues.
Q4 FY25 did not meet investor or management expectations due to a strong dollar impacting Forex earnings.
There was a significant increase in manpower costs as a result of strategic investments in R&D, affecting short-term profitability.
The two-wheeler sector, which accounts for 65% of the company's revenue, experienced muted numbers in Q4 due to regulatory changes.
Export revenues were negatively impacted by new tariffs imposed by the US administration, causing uncertainty among export customers.
The newly acquired plastics business reported lower earnings due to one-time acquisition costs and requires further investment to reach desired margins.
Warning! GuruFocus has detected 1 Warning Sign with BOM:538730.
Q: Can you provide insights into the increase in employee expenses and expectations for the future? A: The increase in employee expenses is primarily due to the addition of R&D staff for product and process development. This is a strategic investment to maintain our competitive edge. While the percentage of sales appears higher due to lower top-line revenue, we expect it to normalize to around 11.5% to 12% as sales increase. The current R&D investments will start yielding results in about 8 to 12 quarters. Vikram Mohan, Managing Director
Q: What impact have raw material price inflation and export mix had on margins? A: The impact on margins is due to raw material price inflation and a slowdown in exports, particularly to the US. However, exports are resuming, and we are firm on pricing despite tariff impacts. We expect normalcy to return in about two quarters. Vikram Mohan, Managing Director
Q: What are the capital requirements for the newly acquired Sundaram business? A: We plan to invest approximately INR 225 to 250 crores over the next four quarters to enhance efficiency, add capacity, and modernize operations. This investment will help improve margins and support top-line growth. Vikram Mohan, Managing Director
Q: Could you provide guidance on revenue growth considering new product developments? A: Our guidance of 13% to 15% growth remains unchanged, even without new products. The new products, expected to start production in FY28 and FY29, will contribute to future growth. Vikram Mohan, Managing Director
Q: What was the impact of the dollar movement on the bottom line? A: The forex impact was about INR 3.5 crores, which will be recovered in Q1 and Q2 of the current financial year. Priyadarshi Bastian, Chief Financial Officer
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
a day ago
- Entrepreneur
Campus Fund Launches USD 100 Mn Fund to Back Student Led Startups
Fund III plans to support up to 60 startups over the next four years, with initial investments ranging from INR 1 crore to INR 8 crore. Half of the fund is reserved for follow-on investments. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Campus Fund, a venture capital firm dedicated to student and dropout-led startups, has announced its largest fund to date—USD 100 million third fund. The firm has already secured more than half of the capital in its first close and has begun deploying funds, with two investments already finalised. Founded by Richa Bajpai in 2020 as a thesis project at London Business School, Campus Fund exclusively supports founders who are currently in university, have dropped out, or graduated within the last three years. Registered as a Sebi Category II Alternative Investment Fund (AIF), it evaluates over 7,000 startups annually through a network of more than 100 student scouts. "This is a full-circle moment for me," said Bajpai, who also co-founded Goodera. "My entrepreneurial journey started in my final year of engineering. To now back students chasing bold ideas, that's the most meaningful chapter of my career." Fund III will support up to 60 startups over the next four years, with initial investments ranging from INR 1 crore to INR 8 crore. Half of the fund is reserved for follow-on investments. Campus Fund's portfolio includes notable startups such as Digantara (space situational awareness), Sama (online dispute resolution), EtherealX (reusable rockets), and GreenGrahi (insect protein). Many have attracted follow-on capital from top firms like Accel, Peak XV Partners, Andreessen Horowitz, AlphaWave, and DST Global. The new fund is backed by a mix of family offices, institutions, and prominent individual investors, including 360 One. Notable limited partners include Kanwaljit Singh (Fireside Ventures), Bharat Shah (HDFC Bank co-founder), Asha Jadeja Motwani, Jaimin Bhatt, and Sameen Farooqui. Campus Fund continues to strengthen its position as a key catalyst for young founders shaping the future.
Entrepreneur
a day ago
- Entrepreneur
Elevation Capital Sells Stake in Ixigo Worth INR 97.4 Cr
Previously, Elevation had also sold INR 100 crore worth of shares in a pre-IPO deal, and another INR 181 crore during the IPO through an offer-for-sale. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Venture capital firm Elevation Capital, formerly known as SAIF Partners, sold 5.4 million shares in online travel platform Ixigo for INR 97.4 crore, marking another significant stake reduction in the company. The shares were offloaded at INR 180.50 per share via its SAIF Partners India IV Limited investment vehicle. On the same day, global fund manager Schroder stepped in as a buyer. Its Asian Total Return Fund purchased 5.37 million shares in Ixigo for INR 96.9 crore, also at INR 180.50 per share, showing continued investor confidence in the travel-tech platform. This marks Elevation's second major sale in recent months. In May, the firm sold 2.15 million shares at INR 178 each, earning INR 38.27 crore. Combined, these transactions total INR 135.7 crore in returns. Elevation Capital, known for early bets on Paytm, Meesho, and Swiggy, originally bought Ixigo shares at just INR 7.14 each, according to the company's draft red herring prospectus (DRHP). This gives the firm an impressive 25X return on its Ixigo investment. Previously, Elevation had also sold INR 100 crore worth of shares in a pre-IPO deal, and another INR 181 crore during the IPO through an offer-for-sale. As of February 2025, it was still the largest institutional shareholder, holding 14% of Ixigo. Ixigo, officially known as Le Travenues Technology Limited, is seeing strong business growth. In Q4 FY25, its revenue from operations jumped 72% year-on-year to INR 284.1 crore, and Gross Transaction Volume (GTV) rose 65% YoY to INR 4,418.4 crore. Flight and bus bookings drove much of this growth with a 92% surge, while train bookings grew by 41%. The company also posted a Profit After Tax of INR 16.8 crore, more than double the INR 7.3 crore in the same quarter last year—an impressive 128% rise, signaling strong financial health and investor interest in the growing travel platform.
Yahoo
2 days ago
- Yahoo
Oscar Health Explodes Higher -- Is This the Market's Next Meme Stock?
June 20 - Oscar Health (NYSE:OSCR) surged more than 18% on Friday, lifting its five-day gain to about 60%, as traders flagged strong momentum indicators and retail interest building around the stock. The rally follows investor commentary on social media, including a post from Ruth Capital highlighting the company's fundamentals. The firm noted Oscar Health's first-quarter performance, which included free cash flow of around $1 billion, as a sign of underlying strength. Traders also pointed to possible indirect political ties, with Oscar Health's co-founder Joshua Kushner being the brother of Jared Kushner, who served in the Trump administration. Market watchers say this connection has drawn attention from retail investors during an election year. Technical signals have added fuel to the stock's run. The moving average convergence divergence, or MACD, remained above its signal line with a positive histogram reading, while the stock price traded above both short- and long-term averages. However, the relative strength index hovered just below 71, indicating the stock may be overbought in the short term. Ruth Capital also warned that heavy reliance on government-backed health programs and earnings volatility could impact performance. Oscar Health shares have climbed nearly 64% so far in 2025 but remain only modestly higher over the past year. This article first appeared on GuruFocus. Sign in to access your portfolio
